A Brazilian Real-Life Experience of Multiple Myeloma Patients: Final Results from the Mmybrave Multi-Center Study

被引：2
|
作者：
Hungria, Vania T. M. [1 ]
Bittencourt, Rosane [2 ]
Martinez, Gracia [3 ]
Santos, Juliana De Andrade [4 ]
de Almeida, Denise Ramos [5 ]
De Piratininga Figueiredo, Vera Lucia [6 ]
Cordeiro De Farias, Danielle Leao [7 ]
Zanella, Karla Richter [8 ]
Muniz, Larissa Barchi [9 ]
Carvalho, Pedro [10 ]
Senra, Juliana [10 ]
Abreu, Rodrigo Martins [10 ]
Mattos, Ederson Roberto [11 ]
机构：
[1] Clin Sao Germano, Sao Paulo, Brazil
[2] Univ Fed Rio Grande do Sul, Hematol Div, Hosp Clin Porto Alegre HCPA, Porto Alegre, RS, Brazil
[3] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil
[4] CEHON Ctr Hematol & Oncol, Salvador, BA, Brazil
[5] Hosp Sao Vicente de Paulo, Passo Fundo, RS, Brazil
[6] Hosp Servidor Publ Sao Paulo, Sao Paulo, Brazil
[7] Univ Fed Goias, Hosp Clin, Goiania, Go, Brazil
[8] CEPON Ctr Pesquisas Oncol, Florianopolis, SC, Brazil
[9] Casa Saude Santa Marcelina, Sao Paulo, Brazil
[10] Takeda Pharmaceut Brazil, Med Affairs, Sao Paulo, Brazil
[11] Fundacao Dr Amaral Carvalho, Ctr Ensino & Pesquisas, Jau, Brazil
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-166762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4352 / 4353
页数：2
相关论文
共 50 条
  • [31] A Real-life study of Alemtuzumab in patients with Multiple Sclerosis: Kuwait's Experience
    Alroughani, Raed
    AlMojel, Malak
    Al-Hashel, Jasem
    Ahmed, Samar
    NEUROLOGY, 2023, 100 (17)
  • [32] REAL LIFE DATA FROM THE FIRST LINE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE OF A THIRD LEVEL CENTER
    Sanchez-Raga, J. M.
    Perez-Montana, A.
    Beltran, N.
    Ros, T.
    Boyeras, B.
    Martorell, C.
    Gutierrez, A.
    Sampol, A.
    HAEMATOLOGICA, 2019, 104 : 194 - 194
  • [33] FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY
    Jakubowiak, A. J.
    Rosenbaum, C. A.
    Stephens, L.
    Kukreti, V.
    Cole, C.
    Zimmerman, T.
    Reece, D.
    Berdeja, J.
    Severson, E.
    Wolfe, B.
    Major, S.
    McDonnell, K.
    Nam, J.
    Turowski, A.
    Griffith, K.
    Zonder, J.
    HAEMATOLOGICA, 2017, 102 : 271 - 271
  • [34] NEXT GENERATION FLOW IN MULTIPLE MYELOMA PATIENTS: A PRELIMINARY REAL-LIFE MULTICENTER MRD HARMONIZATION EXPERIENCE
    Saraci, E.
    Oliva, S.
    Trimarco, V.
    Chiarini, M.
    Parrinello, N. L.
    Zambello, R.
    Cordone, I.
    Masi, S.
    Rossi, G.
    Marino, S.
    Triolo, A. M.
    Roccaro, A.
    Carella, A. M.
    Buccisano, F.
    Belotti, A.
    Consalvo, M. I.
    Romano, A.
    Tonini, A.
    Mercadante, S.
    Bruno, B.
    Terragna, C.
    Zamagni, E.
    HAEMATOLOGICA, 2024, 109 : 110 - 111
  • [35] A REAL LIFE SINGLE CENTER EXPERIENCE OF DARATUMUMAB, LENALDOMIDE AND DEXAMETHASONE COMBINATION IN MULTIPLE MYELOMA PATIENTS
    Attucci, I.
    Formica, G.
    Pilerci, S.
    Buzzichelli, A.
    Messeri, M.
    Vannucchi, A. M.
    Antonioli, E.
    HAEMATOLOGICA, 2021, 106 (10) : 165 - 165
  • [36] Systemic reactions to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis and/or asthma: A real-life, multi-center study
    Xu, Qingxiu
    Jia, Jiaxin
    Lin, Hang
    Liang, Dan
    Chen, Hao
    Wang, Yin
    Gao, Xiang
    Liao, Wang
    Chen, Guohua
    Yang, Lihong
    Zhou, Qianlan
    Bai, Jun
    Xie, Zhihai
    Shan, Lishen
    Zhu, Rongfei
    ALLERGY, 2024,
  • [37] Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study
    Li, Jing
    Bao, Li
    Xia, Zhongjun
    Wang, Sili
    Zhou, Xin
    Ding, Kaiyang
    Zhang, Wenhao
    Yang, Wei
    Li, Bingzong
    Fu, Chengcheng
    Chen, Bing
    Hua, Luoming
    Wang, Liang
    Luo, Jun
    Yang, Yang
    Xu, Tianhong
    Wang, Weida
    Huang, Yun
    Wu, Guolin
    Liu, Peng
    ANNALS OF HEMATOLOGY, 2020, 99 (11) : 2589 - 2598
  • [38] Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study
    Jing Li
    Li Bao
    Zhongjun Xia
    Sili Wang
    Xin Zhou
    Kaiyang Ding
    Wenhao Zhang
    Wei Yang
    Bingzong Li
    Chengcheng Fu
    Bing Chen
    Luoming Hua
    Liang Wang
    Jun Luo
    Yang Yang
    Tianhong Xu
    Weida Wang
    Yun Huang
    Guolin Wu
    Peng Liu
    Annals of Hematology, 2020, 99 : 2589 - 2598
  • [39] Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
    Trudel, Sabrina
    Tessoulin, Benoit
    Jullien, Maxime
    Blin, Nicolas
    Gastinne, Thomas
    Mahe, Beatrice
    Dubruille, Viviane
    Bonnet, Antoine
    Lok, Anne
    Chevallier, Patrice
    Peterlin, Pierre
    Garnier, Alice
    Guillaume, Thierry
    Le Bourgeois, Amandine
    Le Gouill, Steven
    Moreau, Philippe
    Touzeau, Cyrille
    ANNALS OF HEMATOLOGY, 2019, 98 (06) : 1441 - 1447
  • [40] Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
    Sabrina Trudel
    Benoît Tessoulin
    Maxime Jullien
    Nicolas Blin
    Thomas Gastinne
    Béatrice Mahé
    Viviane Dubruille
    Antoine Bonnet
    Anne Lok
    Patrice Chevallier
    Pierre Peterlin
    Alice Garnier
    Thierry Guillaume
    Amandine Le Bourgeois
    Steven Le Gouill
    Philippe Moreau
    Cyrille Touzeau
    Annals of Hematology, 2019, 98 : 1441 - 1447
12345